apremilast,deucravacitinib
amgen,bms
['apremilast', 'poetyk pso,(-poetyk pso1),(-poetyk pso2)', 'psoriasis', 'deucrava', 'deucra']
fda has approvef deucravacitinib (sotyktu), an oral tyk2 inhibitor, for use in adults with moderate-to-severe plaque psoriasis. approval was based on pivotal phase 3 poetyk pso clinical trials demonstrated superior efficacy over pbo &amp; apremilast 
Know-it-Now. Info on RA, Stills disease, Lupus, Gout, Pregnancy, Spondylitis, Psoriasis, Drug Safety, Rheumatology Research, Medical Education & Drug Evaluation